Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

With LAURUSLABS's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.000000
forwardPE 51.488724
debtToEquity 60.048000
earningsGrowth 12.130000
revenueGrowth 0.314000
grossMargins 0.546400
operatingMargins 0.169020
trailingEps 9.430000
forwardEps 23.370000

LAURUSLABS's forward PE ratio is too high, which may hinder future price growth and increase the risk of a price correction. Investors should carefully evaluate this metric along with other key financial indicators to get a full picture of the stock's potential.
Laurus Labs Limited's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that Laurus Labs Limited is expected to continue growing, with rising profits and sales contributing to its long-term success.
LAURUSLABS's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in LAURUSLABS's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

Over time, Laurus Labs Limited's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for Laurus Labs Limited.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


The sell bias toward Laurus Labs Limited from analysts suggests caution, but investors are encouraged to consult a variety of market indicators before making decisions. This broader perspective will help mitigate risks and provide a clearer understanding of Laurus Labs Limited's potential in the current market.